SUTRO BIOPHARMA, INC. (STRO) Form 10-Q — May 14, 2026
Sutro Biopharma reported a net loss of $38.5 million for the first quarter of 2026, driven by $36.6 million in R&D expenses and $7.6 million in G&A costs, though total operating expenses declined 49% year-over-year due to significant restructuring. The company generated $14.5 million in revenue, primarily from collaboration agreements with Astellas, including a $10 million milestone payment for the initiation of a Phase 1 trial. The filing discloses a 1-for-10 reverse stock split that became effective in December 2025 to maintain Nasdaq listing compliance, and a subsequent $110 million equity offering in February 2026 at $13.98 per share.
Key figures
- Revenue
- 14523000
- Total Debt
- 229105000
- Shares Outstanding
- 16570439
- Rd expense
- 36553000
- G a expense
- 7584000
- Offering price
- 13.98
- Shares offered
- 7868383
- Accumulated deficit
- 1016439000
- Restructuring costs
- 42000
- Reverse split ratio
- 1:10
- Offering gross proceeds
- 110000000
Price after filing
Close on the filing date to close N calendar days later (from $38.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.